CLINICAL USEFULNESS OF PROSTATE-SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE IN PATIENTS WITH PROSTATIC-CANCER

被引：15

作者：

FILELLA, X ^{[1
]}

MOLINA, R ^{[1
]}

JO, J ^{[1
]}

UMBERT, B ^{[1
]}

BEDINI, JL ^{[1
]}

BALLESTA, AM ^{[1
]}

机构：

[1] HOSP CLIN BARCELONA,DEPT UROL,E-08036 BARCELONA,SPAIN

来源：

TUMOR BIOLOGY | 1990年 / 11卷 / 06期

关键词：

PAP; Prostatic cancer; PSA;

D O I：

10.1159/000217664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Serum prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) levels were measured in 70 patients with benign prostatic hypertrophy (BPH) and in 70 patients with prostatic cancer. PSA was increased above the cutoff level of 10 ng/ml in 13% of patients with BPH and in 87% of patients with prostatic cancer. In contrast, abnormal PAP levels were found in 14 and 76% of patients, respectively. We concluded that, due to its high specificity, PSA is a useful marker in the management of patients with prostatic carcinoma and that it surpasses PAP in this regard. © 1990 S. Karger AG, Basel.

引用

页码：289 / 294

页数：6

共 18 条

[1] PROSTATIC SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE IN THE MONITORING AND STAGING OF PATIENTS WITH PROSTATIC-CANCER [J].